Home/Pipeline/T-cell Preparation

T-cell Preparation

Multiple Sclerosis

Pre-clinicalActive

Key Facts

Indication

Multiple Sclerosis

Phase

Pre-clinical

Status

Active

Company

Froceth

About Froceth

Froceth is a private, vertically integrated cell therapy company operating in the European advanced therapies space. It develops and manufactures autologous (patient-specific) cell-based products, with a pipeline targeting cancer immunotherapy, multiple sclerosis, and tissue regeneration. The company combines scientific research, clinical trial management, and commercial-scale GMP manufacturing under one roof, positioning itself as a specialized CDMO and therapy developer in a high-growth sector. Its current stage appears to be a mix of pre-clinical/clinical development and commercial service provision.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases Tissue Regeneration

Other Multiple Sclerosis Drugs

Drug	Company	Phase	Status
Mimotopes-003	Mimotopes	Preclinical	Active
SPU-16	Silo Pharma	Preclinical	Research
Electroceutical® Therapy	Endonovo Therapeutics	Research	Active
IMX39	Imunexus Therapeutics	Preclinical	Active
BTK allosteric inhibitor	Acellera	Pre-clinical	Early Hit
CLS12311	Cellerys	Phase 2	Active
Interferon-beta variants	Heligenics	Pre-clinical	Active
G-NK cells	Indapta Therapeutics	Phase 1	Active
MS Biomarker Research	Rune Labs	Research	Active
AVT001	Avotres	Phase 2b	Active
Undisclosed MS Program	Astoria Biologica	Pre-clinical	Active
PV-3212	Provid Pharma	Pre-clinical	Active